EAACI Guidelines

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Abdul Latiff, A., Abuzakouk, M., et al. Allergy. First published: 18 September 2021

---

EAACI guideline: Anaphylaxis (2021 update)

Muraro, A., Worm, M., Alviani, C., et al. Allergy. First published: 03 August 2021

---

EAACI biologicals guidelines – Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Agache, I., Akdis, C., Akdis, M., et al. Allergy. First published: 29 July 2021

---

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Agache, I., Song, Y., Alonso-Coello, P., et al. Allergy. 2021; 76: 2337-2353

---

EAACI biologicals guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

Agache, I., Akdis, C.A., Akdis, M., et al. Allergy. 2021; 76: 988-1009

---

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI biologicals guidelines

Agache, I, Rocha, C, Pereira, A, et al. Allergy. 2021; 76: 59– 70

---

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma

Agache, I, Song, Y, Posso, M, et al. Allergy. 2021; 76: 45– 58

---

EAACI biologicals guidelines—recommendations for severe asthma

Agache, I, Akdis, CA, Akdis, M, et al. llergy. 2021; 76: 14– 44

---

EAACI guideline on the effective transition of adolescents and young adults with allergy and asthma

Roberts, G, Vazquez-Ortiz, M, Knibb, R, et al. Allergy. 2020; 75: 2734– 2752

---

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

Agache, I, Song, Y, Rocha, C, et al. Allergy. 2020; 75: 1058– 1068

---

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Agache, I, Rocha, C, Beltran, J, et al. Allergy. 2020; 75: 1043– 1057

---

Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

Agache, I, Beltran, J, Akdis, C, et al. Allergy. 2020; 75: 1023– 1042

---

EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma

Agache, I, Lau, S, Akdis, CA, et al. Allergy. 2019; 74: 855– 873

---